制药公司Viatris（VTRS）周四盘中大涨5.15%，投资者对公司一季度财报和新药研发进展反应积极。
Viatris公布的第一季度调整后每股收益为50美分，高于分析师预期的49美分。季度收入为32.5亿美元，同样超出市场预期的32.4亿美元。公司品牌药物部门表现强劲，收入同比增长3%至21.2亿美元，主要得益于新兴市场的扩张以及中国市场的强劲需求。
除财报亮眼外，Viatris还宣布其快速起效的非专利止痛药美洛昔康在两项后期研究中达到主要目标，同时其低剂量避孕贴Xulane也在一项后期研究中达到所有主要目标。这些研发进展增强了投资者对公司未来增长潜力的信心。尽管公司报告了29亿美元的商誉减值费用，但投资者似乎更关注其核心业务的改善和研发pipeline的进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.